Océanie · Actualité · The Courier-Mail

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

Publié par The Courier-Mail · Australie il y a 8 h

CSL (ASX:CSL) has ramped up its research and development efforts via a US$355 million ($515m)-plus drug development collab with private Swiss group Alentis Therapeutics.

Lire l'article complet sur The Courier-Mail Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.couriermail.com.au)

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

À lire aussi

Congo boat collision: At least 30 dead and dozens still missing after vessels collide

The best text to speech model, and what it costs you to hear it

Alex de Minaur books a spot in China Open final after semi-final twist

Alex de Minaur books a spot in China Open final after semi-final twist

Alex de Minaur books a spot in China Open final after semi-final twist

Mixed start for pre-Cop as just two non-Pacific leaders accept Australian invitation to climate summit

Health Check: CSL places $500m-plus bet on rare kidney and liver disease drug candidate

Partager

À lire aussi

Congo boat collision: At least 30 dead and dozens still missing after vessels collide

The best text to speech model, and what it costs you to hear it

Alex de Minaur books a spot in China Open final after semi-final twist

Alex de Minaur books a spot in China Open final after semi-final twist

Alex de Minaur books a spot in China Open final after semi-final twist

Mixed start for pre-Cop as just two non-Pacific leaders accept Australian invitation to climate summit